Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Control BionicsASX:CBL -4.92% Days Payable is 82.44 as of Jun. 2026, which is 26% below its 10-year median of 111.53. The stock has 7 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Control Bionics ranks better than 81.56% on this metric.
The historical rank and industry rank for Control Bionics's Days Payable or its related term are showing as below:
ASX:CBL'
s Days Payable Range Over the Past 10 Years
Min: 82.02 Med: 111.53 Max: 176.07
Current: 176.07
During the past 9 years, Control Bionics's highest Days Payable was 176.07. The lowest was 82.02. And the median was 111.53.
ASX:CBL's Days Payable is ranked better than 81.56% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 69.48
vs ASX:CBL: 176.07
Control Bionics's Days Payable
increased
from Jun. 2025 (74.51) to Jun. 2026 (82.44).
It may suggest that Control Bionicsdelayed paying its suppliers.
The historical data trend for Control Bionics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Control Bionics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's Days Payable distribution charts can be found below:
* The bar in red indicates where Control Bionics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Control Bionics's Days Payable for the fiscal year that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) has a Days Payable of 82.44 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Control Bionics and its competitors. This is 26% below median its historical median of 111.53. Over the past decade, Control Bionics' Days Payable has ranged from 82.02 to 176.07. According to the industry distribution chart, Control Bionics ranks #147 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 18.4%.
Is Control Bionics' Days Payable too high?
Control Bionics' current Days Payable of 82.44 is 26% below median its 10-year median of 111.53. Over the past 10 years, this metric has ranged from a low of 82.02 to a high of 176.07. The Medical Devices & Instruments industry median Days Payable is 69.48. Control Bionics' value of 82.44 is 18.7% above this industry median. Based on the distribution chart, Control Bionics ranks #147 out of 797 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Control Bionics' Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #147 out of 797 companies for Days Payable. This places Control Bionics in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 69.48. Control Bionics' value of 82.44 is 18.7% above this benchmark. Historically, Control Bionics' own Days Payable has ranged from 82.02 to 176.07 over the past decade. While the company's 10-year median is 111.53 vs. the industry median of 69.48, Control Bionics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 69.48, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Control Bionics's current Days Payable of 82.44 is 18.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 69.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current Days Payable is 82.44, which is 26% below median its own 10-year median of 111.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.06 — trading 190% above its estimated fair value. The current Days Payable is 82.44, which is 26% below median its 10-year median of 111.53 and 18.7% above the Medical Devices & Instruments industry median of 69.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Days Payable is 82.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 
